![Brian Schryver](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profile
Brian Schryver is the founder of BioCision LLC, which was founded in 2007, where he held the title of Director & Vice President-Product Development.
He is currently the President & Chief Technology Officer at Astero Bio Corp.
since 2018.
Mr. Schryver's former positions include Scientist roles at CFD Therapeutics, Inc. and Corgentech, Inc.
Brian Schryver active positions
Companies | Position | Start |
---|---|---|
Astero Bio Corp.
![]() Astero Bio Corp. Packaged SoftwareTechnology Services Astero Bio Corp. develops novel tools and technologies for the life science research, pharmaceutical manufacturing and clinical applications. It specializes in the development and commercialization of next-generation tools to aid in multiple stages of the lifecycles of biologics. The firm’s products include ThawSTAR CB, ThawSTAR AT6, ThawSTAR CFT2, ThawSTAR CFT2 confirmation vials, IOP qualification packet, BioT ULT transporter, BioT LN2 transporter, and BioT mobile workstation. The company was founded by Samuel Kent in 2018 and is headquartered in Menlo Park, CA. | President | 31/12/2017 |
Former positions of Brian Schryver
Companies | Position | End |
---|---|---|
BioCision LLC
![]() BioCision LLC Medical SpecialtiesHealth Technology BioCision LLC operates as a life science research and development company. Its products include cell cryopreservation systems, sample cooling, freezing, snap-freezing, ice-free cooling systems, tube temperature and plate temperature management, support platforms, sample transport, cryostorage boxes, cryogenic vials, ice pans and buckets and other accessories. The firm’s products protect temperature-sensitive therapeutics, biological samples and biomaterials. The company was founded by Brian Schryver and Rolf O. Ehrhardt in 2007 and is headquartered in San Rafael, CA. | Founder | 31/10/2016 |
Corgentech, Inc. | Corporate Officer/Principal | - |
CFD Therapeutics, Inc.
![]() CFD Therapeutics, Inc. Medical SpecialtiesHealth Technology CFD Therapeutics, Inc. (CFD), is being created to develop novel cancer therapeutics stemming from discoveries made previously by diaDexus. CFD will specifically focus on the development of therapeutic monoclonal antibodies directed against proprietary ovarian, pancreatic, breast, colon, prostate and lung cancer targets licensed from diaDexus. diaDexus, Inc. and San Francisco-based Biotechnology Value Fund L.P | Corporate Officer/Principal | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 4 |
---|---|
BioCision LLC
![]() BioCision LLC Medical SpecialtiesHealth Technology BioCision LLC operates as a life science research and development company. Its products include cell cryopreservation systems, sample cooling, freezing, snap-freezing, ice-free cooling systems, tube temperature and plate temperature management, support platforms, sample transport, cryostorage boxes, cryogenic vials, ice pans and buckets and other accessories. The firm’s products protect temperature-sensitive therapeutics, biological samples and biomaterials. The company was founded by Brian Schryver and Rolf O. Ehrhardt in 2007 and is headquartered in San Rafael, CA. | Health Technology |
CFD Therapeutics, Inc.
![]() CFD Therapeutics, Inc. Medical SpecialtiesHealth Technology CFD Therapeutics, Inc. (CFD), is being created to develop novel cancer therapeutics stemming from discoveries made previously by diaDexus. CFD will specifically focus on the development of therapeutic monoclonal antibodies directed against proprietary ovarian, pancreatic, breast, colon, prostate and lung cancer targets licensed from diaDexus. diaDexus, Inc. and San Francisco-based Biotechnology Value Fund L.P | Health Technology |
Corgentech, Inc. | Health Technology |
Astero Bio Corp.
![]() Astero Bio Corp. Packaged SoftwareTechnology Services Astero Bio Corp. develops novel tools and technologies for the life science research, pharmaceutical manufacturing and clinical applications. It specializes in the development and commercialization of next-generation tools to aid in multiple stages of the lifecycles of biologics. The firm’s products include ThawSTAR CB, ThawSTAR AT6, ThawSTAR CFT2, ThawSTAR CFT2 confirmation vials, IOP qualification packet, BioT ULT transporter, BioT LN2 transporter, and BioT mobile workstation. The company was founded by Samuel Kent in 2018 and is headquartered in Menlo Park, CA. | Technology Services |
- Stock Market
- Insiders
- Brian Schryver